635 related articles for article (PubMed ID: 17545524)
21. A 39-gene signature is associated with early occurrence of distant metastasis in primary lymph-node negative breast cancers.
Xia R; Chen S; Zhang W; Chen Y; Zhu R; Deng A
Neoplasma; 2015; 62(5):821-6. PubMed ID: 26278156
[TBL] [Abstract][Full Text] [Related]
22. Identification of a New Eight-Long Noncoding RNA Molecular Signature for Breast Cancer Survival Prediction.
Zhang Y; Li Z; Chen M; Chen H; Zhong Q; Liang L; Li B
DNA Cell Biol; 2019 Dec; 38(12):1529-1539. PubMed ID: 31647329
[TBL] [Abstract][Full Text] [Related]
23. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
24. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
25. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer.
Maak M; Simon I; Nitsche U; Roepman P; Snel M; Glas AM; Schuster T; Keller G; Zeestraten E; Goossens I; Janssen KP; Friess H; Rosenberg R
Ann Surg; 2013 Jun; 257(6):1053-8. PubMed ID: 23295318
[TBL] [Abstract][Full Text] [Related]
26. Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Elger T; Krajnak S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
Breast Cancer Res Treat; 2017 Sep; 165(2):293-300. PubMed ID: 28585074
[TBL] [Abstract][Full Text] [Related]
27. Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification.
Nuyten DS; Hastie T; Chi JT; Chang HY; van de Vijver MJ
Eur J Cancer; 2008 Oct; 44(15):2319-29. PubMed ID: 18715778
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy.
Sjöström M; Chang SL; Fishbane N; Davicioni E; Hartman L; Holmberg E; Feng FY; Speers CW; Pierce LJ; Malmström P; Fernö M; Karlsson P
Clin Cancer Res; 2020 Jan; 26(1):171-182. PubMed ID: 31558478
[TBL] [Abstract][Full Text] [Related]
29. Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
Aalders KC; Kuijer A; Straver ME; Slaets L; Litiere S; Viale G; Van't Veer LJ; Glas AM; Delorenzi M; van Dalen T; Tryfonidis K; Piccart MJ; Cardoso F; Rutgers EJ;
Eur J Cancer; 2017 Jul; 79():98-105. PubMed ID: 28477490
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
[TBL] [Abstract][Full Text] [Related]
31. Unravelling site-specific breast cancer metastasis: a microRNA expression profiling study.
Schrijver WA; van Diest PJ; ; Moelans CB
Oncotarget; 2017 Jan; 8(2):3111-3123. PubMed ID: 27902972
[TBL] [Abstract][Full Text] [Related]
32. High-resolution genomic profiling to predict 10-year overall survival in node-negative breast cancer.
Möllerström E; Delle U; Danielsson A; Parris T; Olsson B; Karlsson P; Helou K
Cancer Genet Cytogenet; 2010 Apr; 198(2):79-89. PubMed ID: 20362222
[TBL] [Abstract][Full Text] [Related]
33. PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.
Tobin NP; Lundberg A; Lindström LS; Harrell JC; Foukakis T; Carlsson L; Einbeigi Z; Linderholm BK; Loman N; Malmberg M; Fernö M; Czene K; Perou CM; Bergh J; Hatschek T;
Clin Cancer Res; 2017 Dec; 23(23):7225-7231. PubMed ID: 28972041
[No Abstract] [Full Text] [Related]
34. A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer.
Chen X; Wang YW; Zhu WJ; Li Y; Liu L; Yin G; Gao P
Hum Pathol; 2018 Jun; 76():122-132. PubMed ID: 29555574
[TBL] [Abstract][Full Text] [Related]
35. Prediction of breast cancer metastasis risk using circulating tumor markers: A follow-up study.
Cetintas S; Tezcan G; Tunca B; Egeli U; Gokgoz MS; Cecener G
Bosn J Basic Med Sci; 2019 May; 19(2):172-179. PubMed ID: 30242807
[TBL] [Abstract][Full Text] [Related]
36. Design and multiseries validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival.
Van Laar RK
J Mol Diagn; 2011 May; 13(3):297-304. PubMed ID: 21458382
[TBL] [Abstract][Full Text] [Related]
37. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Filipits M; Rudas M; Jakesz R; Dubsky P; Fitzal F; Singer CF; Dietze O; Greil R; Jelen A; Sevelda P; Freibauer C; Müller V; Jänicke F; Schmidt M; Kölbl H; Rody A; Kaufmann M; Schroth W; Brauch H; Schwab M; Fritz P; Weber KE; Feder IS; Hennig G; Kronenwett R; Gehrmann M; Gnant M;
Clin Cancer Res; 2011 Sep; 17(18):6012-20. PubMed ID: 21807638
[TBL] [Abstract][Full Text] [Related]
38. A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences.
Mittempergher L; Saghatchian M; Wolf DM; Michiels S; Canisius S; Dessen P; Delaloge S; Lazar V; Benz SC; Tursz T; Bernards R; van't Veer LJ
Mol Oncol; 2013 Oct; 7(5):987-99. PubMed ID: 23910573
[TBL] [Abstract][Full Text] [Related]
39. Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures.
Huang CC; Tu SH; Lien HH; Huang CS; Huang CJ; Lai LC; Tsai MH; Chuang EY
Breast Cancer Res Treat; 2014 Sep; 147(2):353-70. PubMed ID: 25158930
[TBL] [Abstract][Full Text] [Related]
40. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.
Pawitan Y; Bjöhle J; Amler L; Borg AL; Egyhazi S; Hall P; Han X; Holmberg L; Huang F; Klaar S; Liu ET; Miller L; Nordgren H; Ploner A; Sandelin K; Shaw PM; Smeds J; Skoog L; Wedrén S; Bergh J
Breast Cancer Res; 2005; 7(6):R953-64. PubMed ID: 16280042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
